- Home
- GNTA vs MAIA Comparison
GNTA vs MAIA Comparison
Compare GNTA & MAIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GNTA | MAIA |
|---|---|---|
| Founded | 2014 | 2018 |
| Country | Italy | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 34.0M | 49.3M |
| IPO Year | 2021 | 2022 |
Fundamental Metrics
Financial Performance| Metric | GNTA | MAIA |
|---|---|---|
| Price | $1.42 | $1.60 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 100.9K | ★ 923.3K |
| Earning Date | 03-30-2026 | 11-07-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.28 | $0.87 |
| 52 Week High | $10.00 | $2.74 |
Technical Indicators
Market Signals| Indicator | GNTA | MAIA |
|---|---|---|
| Relative Strength Index (RSI) | 36.77 | 60.65 |
| Support Level | $1.28 | $1.33 |
| Resistance Level | $1.59 | $1.64 |
| Average True Range (ATR) | 0.19 | 0.16 |
| MACD | 0.03 | 0.02 |
| Stochastic Oscillator | 24.49 | 72.58 |
Price Performance
Historical ComparisonAbout GNTA Genenta Science S.p.A.
Genenta Science SPA is a clinical-stage biotechnology company engaged in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors and cancer. The company's products include Temferon - a product to treat glioblastoma multiforme, a solid tumor affecting the brain.
About MAIA MAIA Biotechnology Inc.
MAIA Biotechnology Inc is a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer. THIO (6-thio-dG or 6-thio-2 '-deoxyguanosine), its lead asset, is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. Patients with advanced NSCLC will be treated first with THIO followed a few days later by the immune checkpoint inhibitor Libtayo (cemiplimab), manufactured and commercialized by Regeneron.